Table 7.
Visual score of DNA damage in 7 and 15 treated PACA2, 7 treated PC3, 8 treated A549, and 7 and 9 treated HCT116. Doxorubicin was used as a positive control.
| Treatment | Cell line | No. of samples | No. of cells | Class** | DNA damaged cells % (mean ± SEM) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Analyzed* | Comets | 0 | 1 | 2 | 3 | ||||
| Untreated cells | PACA2 | 4 | 400 | 43 | 357 | 31 | 10 | 2 | 10.76 ± 1.11b |
| 7 | 4 | 400 | 94 | 306 | 35 | 28 | 31 | 23.52 ± 0.65a | |
| 15 | 4 | 400 | 84 | 316 | 31 | 25 | 28 | 21.00 ± 1.29a | |
| Doxorubicin | 4 | 400 | 81 | 319 | 28 | 26 | 27 | 20.25 ± 0.75a | |
| Untreated cells | PC3 | 4 | 400 | 41 | 359 | 29 | 11 | 1 | 10.27 ± 0.85c |
| 7 | 4 | 400 | 103 | 297 | 38 | 36 | 29 | 25.78 ± 1.44a | |
| Doxorubicin | 4 | 400 | 83 | 317 | 39 | 30 | 14 | 20.76 ± 1.38b | |
| Untreated cells | A549 | 4 | 400 | 43 | 357 | 36 | 7 | 0 | 10.79 ± 0.48b |
| 8 | 4 | 400 | 99 | 301 | 39 | 38 | 22 | 24.75 ± 1.03a | |
| Doxorubicin | 4 | 400 | 86 | 314 | 25 | 32 | 29 | 21.52 ± 1.04a | |
| Untreated cells | HCT116 | 4 | 400 | 42 | 358 | 31 | 8 | 3 | 10.53 ± 1.19c |
| 7 | 4 | 400 | 102 | 298 | 29 | 38 | 35 | 25.56 ± 0.66a | |
| 9 | 4 | 400 | 79 | 321 | 37 | 24 | 18 | 19.75 ± 1.25b | |
| Doxorubicin | 4 | 400 | 85 | 315 | 33 | 24 | 28 | 21.26 ± 0.48ab | |
*Number of cells examined per a group, **Class 0 = no tail; 1 = tail length < diameter of nucleus; 2 = tail length between 1 and 2 × the diameter of nucleus; and 3 = tail length > 2 × the diameter of nucleus. a–cMean values within tissue with unlike superscript letters were significantly different (P < 0.05).